Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 23, 1999

View Archived Issues

Company Profile: Ibex Technologies

Oxigene: Q4 1998 highlights

Xenometrix grants gene expression profiling patent license to Genzyme

Calmodulin analogues with antiinflammatory activity available for licensing from OMRF

Trial results of rhVEGF165 in CAD disappointing

Autoimmune antibodies linked to blood clotting defect

Trimera mouse model for human HBV described

U.S. patent covers fundamental basis of Prolifix's R&D program

Tissue factor inhibition: another mechanism linked to the cardiovascular effects of resveratrol

Janssen presents selective IL-5 production inhibitors for allergic and inflammatory disorders

Novel heterocyclic CRF antagonists under study at DuPont

Antiproliferative agents from Warner-Lambert act by inhibiting MEK kinase

Roche's new antimalarial compounds active against chloroquine-sensitive and -resistant pathogens

Dopamine D3 ligands in the BASF pipeline

Bracco launches new ultrasound image-enhancing agent in U.S.

Activity of novel deoxyadenosine analogue investigated against human colon tumors

Licensing opportunity from NIH: mixture of MAbs to treat respiratory infections

New combination product represents a highly effective approach to acne vulgaris

Raloxifene's effects on mood and cognitive function assessed

V2 antagonist OPC-31260 prevents cerebral edema in rat model

British Biotech: Q3 and nine-month highlights

New combination treatment for pain now available in U.S.

Newly issued patent provides further protection for Diatide's lead imaging agents

Ribozyme issued U.S. patent for ribozyme HCV therapeutics

New obesity management drug approved in worldwide markets

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...